Brought to you by 
Impax acquires generic drug portfolio from Teva; Teva returns rights to ANDA for generic Concerta
03 Feb 2023
Executive Summary
Impax Laboratories Inc. acquired a portfolio of 18 marketed, approved and pipeline generics from Teva Pharmaceutical Industries Ltd. and Allergan affiliates for $586mm (funded from $400mm in new term loans with the balance from cash on hand). The product divestitures were mandated by the FTC as a condition of Teva's pending acquisition of Allergan's global generics business (just last week Teva sold off the rights to eight ANDAs to Dr. Reddy's.)
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Impax acquires generic drug portfolio from Teva; Teva returns rights to ANDA for generic Concerta
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice